BioCardia, Inc.
Business
BioCardia, Inc. is a publicly listed company in Biological Products, (No Diagnostic Substances), incorporated in Delaware. Common stock trades on Nasdaq under the ticker BCDA.
Auto-generated from company profile
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration agreement revenue | 0 | 58,000 | 477,000 | 1 | 1 | |
| Research and development | 5 | 4 | 8 | 9 | 9 | |
| Selling, general and administrative | 3 | 4 | 4 | 4 | 5 | |
| Total costs and expenses | 8 | 8 | 12 | 13 | 14 | |
| Operating loss | −8 | −8 | −12 | −12 | −13 | |
| Total other income, net | 50,000 | 55,000 | 73,000 | −6,000 | 7,000 | |
| Net loss | −8 | −8 | −12 | −12 | −13 | |
| Net loss per share, basic and diluted (in dollars per share) | −1.23 | −2.9 | −8.19 | −0.67 | −0.75 | |
| Weighted-average shares used in computing net loss per share, basic and diluted (in shares) | 7 | 3 | 1 | 18 | 17 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3 | 2 | 1 | 7 | 13 | |
| Accounts receivable, net of allowance for doubtful accounts of $0 and $0 as of December 31, 2025 and 2024, respectively | 20,000 | 0 | 63,000 | 201,000 | 147,000 | |
| Prepaid expenses | 216,000 | 251,000 | 295,000 | 300,000 | 462,000 | |
| Total current assets | 3 | 3 | 1 | 8 | 13 | |
| Property and equipment, net | 16,000 | 33,000 | 94,000 | 170,000 | 182,000 | |
| Operating lease right-of-use asset, net | 494,000 | 898,000 | 1 | 2 | 2 | |
| Other assets | 171,000 | 171,000 | 171,000 | 171,000 | 172,000 | |
| Total assets | 3 | 4 | 3 | 10 | 16 | |
| Accounts payable | 641,000 | 385,000 | 890,000 | 683,000 | 507,000 | |
| Accrued expenses and other current liabilities | 1 | 2 | 2 | 2 | 2 | |
| Operating lease liability - current | 442,000 | 385,000 | 333,000 | 315,000 | 237,000 | |
| Total current liabilities | 2 | 2 | 4 | 4 | 4 | |
| Operating lease liability - noncurrent | 86,000 | 566,000 | 982,000 | 1 | 2 | |
| Total liabilities | 3 | 3 | 5 | 5 | 5 | |
| Commitments and Contingencies | — | — | — | — | — | |
| Preferred stock, $0.001 par value, 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.001 par value, 50,000,000 shares authorized, 10,755,647 and 4,600,910 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 11,000 | 5,000 | 2,000 | 20,000 | 17,000 | |
| Additional paid-in capital | 169 | 161 | 151 | 145 | 139 | |
| Accumulated deficit | −168 | −160 | −152 | −141 | −129 | |
| Total stockholders equity | 895,000 | 837,000 | −2 | 5 | 10 | |
| Total liabilities and stockholders equity | 3 | 4 | 3 | 10 | 16 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 24,000 | 67,000 | 84,000 | 82,000 | 60,000 | |
| Reduction in the carrying amount of right-of-use assets | 481,000 | 482,000 | 327,000 | 295,000 | 580,000 | |
| Share-based compensation | 430,000 | 741,000 | 1 | 1 | 2 | |
| Allowance for doubtful accounts | 0 | −34,000 | 23,000 | — | — | |
| Accounts receivable | 20,000 | −97,000 | −115,000 | 54,000 | 85,000 | |
| Prepaid expenses | 35,000 | 44,000 | −5,000 | −163,000 | −179,000 | |
| Accounts payable | 163,000 | −316,000 | 184,000 | 4,000 | −239,000 | |
| Accrued expenses and other current liabilities | 179,000 | −538,000 | 482,000 | 416,000 | 130,000 | |
| Operating lease liability | −500,000 | −483,000 | −316,000 | — | — | |
| Net cash used in operating activities | −7 | −8 | −10 | −11 | −10 | |
| Purchase of property and equipment | −7,000 | −6,000 | −12,000 | −70,000 | −116,000 | |
| Net cash used in investing activities | −7,000 | −6,000 | −12,000 | −70,000 | −116,000 | |
| Exercise of common stock warrants | 5,000 | 0 | — | — | — | |
| Taxes paid related to net share settlement of equity awards | −197,000 | −140,000 | — | — | 0 | |
| Proceeds from sales of common stock | 9 | 11 | 4 | 6 | 2 | |
| Issuance costs of sale of common stock | −930,000 | −1 | 662,000 | 418,000 | −59,000 | |
| Net cash provided by financing activities | 8 | 9 | 4 | 5 | 2 | |
| Net change in cash and cash equivalents | 125,000 | 1 | −6 | −6 | −9 | |
| Unpaid issuance costs of common stock | 99,000 | 6,000 | 195,000 | 172,000 | 0 | |
| Restricted stock units issued to settle management bonus obligations | 184,000 | 156,000 | 564,000 | 401,000 | 393,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is BioCardia, Inc.'s CIK number?
BioCardia, Inc.'s SEC CIK number is 0000925741 (925741). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find BioCardia, Inc.'s SEC filings?
All of BioCardia, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did BioCardia, Inc. last report earnings?
BioCardia, Inc. (BCDA) most recently filed an earnings 8-K with the SEC on May 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-017222). This is BioCardia, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is BioCardia, Inc.'s most recent earnings 8-K?
BioCardia, Inc.'s latest earnings 8-K (Item 2.02) was filed May 15, 2026 under accession 0001437749-26-017222. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View BioCardia, Inc.'s latest earnings 8-K →
Look up any company's CIK number →